polaris peptides retatrutide RETATRUTIDE (RETA)

The recommended doses for this group are peginterferon alpha-2b, 1 g/kg subcutaneously once weekly or peginterferon alfa-2a, 135 g subcutaneously once weekly, together with ribavirin, 200 to 800 mg per day in 2 divided doses, starting with the low dose and increasing gradually as long as side effects are minimal and manageable

The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549

Temporary use may appeal to those wanting short-term results, but providers generally discuss this as a sustained commitment

These mechanisms are plausible but not proven to be causal for new-onset vaginal pathology